Recombinant factor VIIa for rapid reversal of warfarin anticoagulation in acute intracranial hemorrhage.

@article{Freeman2004RecombinantFV,
  title={Recombinant factor VIIa for rapid reversal of warfarin anticoagulation in acute intracranial hemorrhage.},
  author={W. Freeman and T. Brott and K. Barrett and P. Castillo and H. G. Deen and L. Czervionke and J. Meschia},
  journal={Mayo Clinic proceedings},
  year={2004},
  volume={79 12},
  pages={
          1495-500
        }
}
OBJECTIVE To assess the effects of recombinant factor VIIa (rFVIIa) on hemorrhage volume and functional outcomes in warfarin-related acute intracranial hemorrhage (ICH), which has a 30-day mortality of more than 50%. PATIENTS AND METHODS We reviewed the clinical, laboratory, and radiographic features of a consecutive series of 7 patients (median age, 87 years; 5 women) with symptomatic, nontraumatic warfarin-related acute ICH treated with intravenous rFVIIa at St. Luke's Hospital in… Expand
Recombinant factor VIIa for warfarin-associated intracranial bleeding.
TLDR
Factor rVIIa provides prompt correction of the INR of dose-dependent duration in patients with ICH intracranial hemorrhage associated with warfarin use. Expand
Recombinant factor VIIa use in patients presenting with intracranial hemorrhage
TLDR
Recombinant factor VIIa appears to lower INR without significant thromboembolic complications and doses used and adverse effects caused by rFVIIa administration are reviewed. Expand
Coagulation factor VIIa (recombinant) for warfarin-induced intracranial hemorrhage.
  • A. Rowe, R. M. Turner
  • Medicine
  • American journal of health-system pharmacy : AJHP : official journal of the American Society of Health-System Pharmacists
  • 2010
TLDR
Use of factor VIIa (recombinant) may be considered for reversal of anticoagulation in patients with warfarin-associated ICH, but patients should be screened for increased risk of thrombosis before administration of the drug. Expand
Safety of Recombinant Activated Factor VII in Patients With Warfarin-Associated Hemorrhages of the Central Nervous System
TLDR
The risk of thromboembolic events in patients who received recombinant Factor VIIa for anticoagulation-associated ICH was not higher than that seen in patients treated for spontaneous ICH in the Factor Seven for Acute Hemorrhagic Stroke (FAST) trial. Expand
Treatment of warfarin-related intracranial hemorrhage: a comparison of prothrombin complex concentrate and recombinant activated factor VII.
OBJECTIVE Warfarin-related intracranial hemorrhage (ICH) is a devastating complication of warfarin therapy. Several studies have demonstrated successful correction of the international normalizedExpand
A meta-analysis of the efficacy and safety of recombinant activated factor VII for patients with acute intracerebral hemorrhage without hemophilia
TLDR
Although rFVIIa can reduce the change in ICH volume, there was no significant difference in mortality, modified Rankin Scale (mRS) score or extended Glasgow Outcome Scale (GOS-E) score in patients treated with rF VIIa or placebo and rFVI increases the incidence of arterial TAE. Expand
Effectiveness of Factor IX Complex Concentrate in Reversing Warfarin Associated Coagulopathy for Intracerebral Hemorrhage
TLDR
The data suggests that FIXCC in combination with FFP and Vit.K may result in decreased time required for correction of warfarin associated coagulopathy in neurosurgical emergencies. Expand
Prothrombin Complex Concentrates for Urgent Anticoagulation Reversal in Patients with Intracranial Haemorrhage
TLDR
PCC administration is an effective, rapid and safe treatment for the urgent reversal of OAT in patients with ICH, and broader use of PCC in this clinical setting appears to be appropriate. Expand
Timing of Fresh Frozen Plasma Administration and Rapid Correction of Coagulopathy in Warfarin-Related Intracerebral Hemorrhage
TLDR
Although additional study is required to determine the clinical benefit of rapid reversal of anticoagulation, minimizing delays in FFP administration is a prudent first step in emergency management of warfarin-related ICH. Expand
Prothrombin Complex Concentrate for Rapid Reversal of Warfarin-induced Anticoagulation and Intracerebral Hemorrhage in Patients Supported by a Left Ventricular Assist Device
TLDR
Patients on LVAD are in need for intensified anticoagulation and are at high risk of ICH; therefore, adequate use of prothrombin complex concentrate in the event of I CH could be of importance for survival and allow subsequent heart transplantation. Expand
...
1
2
3
4
5
...

References

SHOWING 1-10 OF 24 REFERENCES
The use of recombinant activated factor VII to reverse warfarin-induced anticoagulation in patients with hemorrhages in the central nervous system: preliminary findings.
TLDR
Clinical experience indicates that rFVIIa may be safe and effective as the initial hemostatic agent for rapid reversal of orally administered anticoagulation medications in patients who require urgent neurosurgical intervention. Expand
Reversal of the International Normalized Ratio with recombinant activated factor VII in central nervous system bleeding during warfarin thromboprophylaxis: clinical and biochemical aspects
TLDR
Ex-vivo experiments and clinical data support recent suggestions that rFVIIa might substitute for infusion of FFP or PCC in acute reversal of VKA treatment, and return a distinct reduction of the prolonged initiation but variable changes in the maximum velocity of clot formation. Expand
The effect of warfarin and intensity of anticoagulation on outcome of intracerebral hemorrhage.
TLDR
Patients taking warfarin had a doubling in the rate of intracerebral hemorrhage mortality in a dose-dependent manner, and the data suggest that careful control of the INR, already known to limit the risk of warFarin-related ICH, may also limit its severity. Expand
Predisposing factors for enlargement of intracerebral hemorrhage in patients treated with warfarin.
TLDR
An INR value of >2.0 within 24 h of ICH seems an important predisposing factor for ICH enlargement, which is similar to that shown in patients treated for intracerebral hematoma during warfarin therapy. Expand
Reversal of Warfarin-Induced Excessive Anticoagulation with Recombinant Human Factor VIIa Concentrate
TLDR
It is shown that a single infusion of human recombinant factor VIIa concentrate (rFVIIa) immediately reduced international normalized ratios without adverse effects in 13 patients who needed rapid reversal of excessive warfarin-induced anticoagulation for various reasons. Expand
Management and Prognostic Features of Intracerebral Hemorrhage During Anticoagulant Therapy: A Swedish Multicenter Study
TLDR
In AC-related ICH, a progressive neurological deterioration during the first 24 to 48 hours after admission is frequent, and the mortality is high, and choice of therapy to reverse the AC effect differed considerably between the hospitals. Expand
What causes intracerebral hemorrhage during warfarin therapy?
TLDR
Although warfarin and related oral vitamin K antagonists have been used for stroke prevention for 50 years, more cases of anticoagulant-associated intracerebral bleeding are now reported—up to one per month at some tertiary referral hospitals, most occurring when the international normalized ratio (INR) is within the therapeutic range. Expand
Ongoing NovoSeven® trials
TLDR
The mechanism of action of recombinant activated factor VII suggests that its enhancing effects in haemostasis are limited to the site of injury and that systemic activation of the coagulation cascade does not occur, which suggests that rFVIIa may be valuable as a general haemOSTatic agent. Expand
Can Patients Be Anticoagulated After Intracerebral Hemorrhage?: A Decision Analysis
TLDR
Survivors of lobar ICH with atrial fibrillation should not be offered long-term anticoagulation, but patients with deep hemispheric ICH at particularly high risk for thromboembolic stroke or low risk of ICH recurrence might benefit from long- Term Anticoagulant therapy. Expand
Safety of discontinuation of anticoagulation in patients with intracranial hemorrhage at high thromboembolic risk.
TLDR
Discontinuation of warfarin therapy for 1 to 2 weeks has a comparatively low probability of embolic events in patients at high embolic risk, and should be taken into consideration when deciding whether to continue or discontinue anticoagulation in patients with ICH at high thromboembolic risk. Expand
...
1
2
3
...